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Abstract
Background: National guidance on preventing type 2 diabetes mellitus (T2DM) in the UK recommends low-intensity
lifestyle interventions for individuals with intermediate categories of hyperglycaemia defined in terms of impaired fasting
glucose (IFG) or ‘at-risk’ levels of HbA1c. In a recent systematic review of economic evaluations of such interventions, most
studies had evaluated intensive trial-based lifestyle programmes in participants with impaired glucose tolerance (IGT). This
study examines the costs and effects of different intensity lifestyle programmes and metformin in participants with
different categories of intermediate hyperglycaemia.
Methods: We developed a decision tree and Markov model (50-year horizon) to compare four approaches, namely (1)
a low-intensity lifestyle programme based on current NICE guidance, (2) a high-intensity lifestyle programme based on
the US Diabetes Prevention Program, (3) metformin, and (4) no intervention, modelled for three different types of
intermediate hyperglycaemia (IFG, IGT and HbA1c). A health system perspective was adopted and incremental
analysis undertaken at an individual and population-wide level, taking England as a case study.
Results: Low-intensity lifestyle programmes were the most cost-effective (£44/QALY, £195/QALY and £186/
QALY compared to no intervention in IGT, IFG and HbA1c, respectively). Intensive lifestyle interventions were
also cost-effective compared to no intervention (£2775/QALY, £6820/QALY and £7376/QALY, respectively, in IGT, IFG
and HbA1c). Metformin was cost-effective relative to no intervention (£5224/QALY, £6842/QALY and £372/QALY in IGT,
IFG and HbA1c, respectively), but was only cost-effective relative to other treatments in participants identified
with HbA1c. At a willingness-to-pay threshold of £20,000/QALY, low- and high-intensity lifestyle programmes
were cost-effective 98%, 99% and 98% and 81%, 81% and 71% of the time in IGT, IFG and HbA1c, respectively. An
England-wide programme for 50–59 year olds could reduce T2DM incidence by < 3.5% over 50 years and would cost
0.2–5.2% of the current diabetes budget for 2–9 years.
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Discussion: This analysis suggests that current English national policy of low-intensity lifestyle programmes in participants
with IFG or HbA1c will be cost-effective and have the most favourable budget impact, but will prevent only a fraction of
cases of T2DM. Additional approaches to prevention need to be investigated urgently.
Keywords: Diabetes prevention, Prediabetes, Intermediate hyperglycaemia, Economic evaluation, Impaired fasting
glucose, Impaired glucose tolerance, HbA1c in at-risk range, Cost-effective
Background
Diabetes mellitus is a global health priority, with a high
prevalence (9% of adults globally are estimated to have the
disease) and a substantial economic burden (accounting
for 12% of global health expenditure). Cost is predicted to
rise from $1.197 billion in 2015 to $1.452 billion by 2040
due to the increased prevalence of risk factors for diabetes,
such as obesity, and the ageing of the world’s population
[1]. By 2040, according to current trends, prevalence could
be 642 million [1].
A number of large trials in the US [2], China [3],
Finland [4] and India [5] have shown that type 2 diabetes
mellitus (T2DM) can be prevented or delayed through
lifestyle programmes or metformin in individuals with
measures of glycaemia lower than those required to
diagnose diabetes, but higher than ‘normal’. Lifestyle
programmes included in these trials were intensive and
sustained, provided by specialist staff over 3–10 years.
Subsequent translation of these programmes into ‘real-
world’ settings led to shorter programmes (3–24 months
long) delivered by non-specialist staff, with more limited
impact on the incidence of T2DM [6, 7].
Participants for diabetes prevention programmes are
identified by the presence of ‘prediabetes’ or intermedi-
ate hyperglycaemia (measures of glycaemia lower than
those required to diagnose T2DM, but higher than
‘normal’) or an assessment of risk of developing diabetes
in the future (e.g. through the use of diabetes risk
scores) [8]. Intermediate hyperglycaemia is a generic
term that includes impaired fasting glucose (IFG), im-
paired glucose tolerance (IGT) and HbA1c in the
‘at-risk’ range. These different types of prediabetes differ
in terms of their physiology, prevalence, progression to
T2DM and their response to prevention programmes
[9–12]. For example, while the evidence base for
diabetes prevention among people with IGT is robust,
few interventional studies exist for participants with
isolated IFG and, to our knowledge, no randomised
controlled trials have examined the effect on progression
to T2DM in participants with isolated HbA1c in the
at-risk range.
Given the increasing impact on populations and health
budgets, the burden of T2DM is a key issue for policy-
makers. Diabetes prevention guidance issued by the
National Institute of Clinical Excellence (NICE) in the
UK and the Preventative Services Task Force in the US
favours low-intensity lifestyle programmes [13, 14],
focused on participants with IFG or ‘at-risk’ HbA1c in
the UK. However, our recent systematic review [15]
showed that there are few economic evaluations of these
type of interventions, and the majority of those that do
exist use treatment effects drawn from the trials evaluating
more intensive lifestyle programmes in participants with
IGT. To date, the generalisability of this assumption has
not been validated. Additionally, no evaluation, to our
knowledge, compares a pragmatic lifestyle programme with
metformin or programmes for participants with ‘at-risk’
HbA1c with those offered to participants with other types
of intermediate hyperglycaemia.
Research question
This study evaluates the gap between existing evidence and
current policy, exploring (1) the impact of the type of
prediabetes chosen as the entry criteria for a programme,
(2) the role of metformin versus low-intensity lifestyle
programmes, and (3) the impact of the intensity of the life-
style programme offered. This was analysed by modelling
the cost and consequences (in terms of quality-adjusted
life-years (QALY), incident cases of T2DM and average
number of years with T2DM) for:
1. Three different definitions of intermediate
hyperglycaemia (IFG, HbA1c, IGT) used to select
participants for diabetes prevention programmes,
and
2. Three types of diabetes prevention programme
(metformin, intensive trial-based lifestyle
programme, low-intensity pragmatic lifestyle
programme)
A number of economic evaluations of lifestyle
programmes and metformin for the prevention of
diabetes have been undertaken [16–19]. To our know-
ledge, this is the first to compare (1) differences between
participants with IFG, IGT and HbA1c, and (2) different
intensities of lifestyle intervention with metformin. In
addition, this is the first review to utilise data from
recent meta-analyses of treatment effects in randomised
controlled trials for lifestyle programmes [8, 15, 20, 21].
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Methods
A de novo economic model (decision tree and Markov
model) was developed in TreeAgePro (TreeAge Software
Inc.). An NHS perspective was adopted for the analysis.
The price year was 2015 and the costs were reported in
Great British Pound Sterling (£). The model structure
was developed following a review of intervention trials [8]
and cost-effectiveness analyses [15] and verified with a
multi-disciplinary clinical team in Newham, East London,
who were engaged in developing a Borough-wide diabetes
prevention programme. The model comprised four health
states (normoglycaemia, intermediate hyperglycaemia
(either IFG, IGT or HbA1c), T2DM and death). The out-
comes of the analysis were cost per QALY gained, where
the QALYs were calculated using SF-6D utility values. We
adopted a 50-year time horizon with annual cycles. Costs
and utilities were discounted by an annual discount
rate of 3.5% per year, which is the rate recommended
by NICE [22].
Both deterministic and probabilistic models were
evaluated; the probabilistic model was used to account
for non-linearity and correlations in parameters and to
characterise the decision uncertainty. Deterministic
sensitivity analysis was undertaken to evaluate alterna-
tive scenarios where there are differences in definitions
(e.g. American Diabetes Association or World Health
Organization (WHO) diagnostic criteria) or primary
clinical data is not available (e.g. long-term effect of
interventions).
Three populations were evaluated in the model, namely
individuals with IFG, IGT and HbA1c in the ‘at-risk’ range,
across 12 different diagnosis-treatment pairs: IGT_prag-
matic lifestyle, IGT_intensive lifestyle, IGT_metformin,
IGT_no intervention, IFG_pragmatic lifestyle, IFG_inten-
sive lifestyle, IFG_metformin, IFG_no intervention,
HbA1c_pragmatic lifestyle, HbA1c_intensive lifestyle,
HbA1c_metformin, and HbA1c_no intervention.
Model structure
We assumed that the population entered the model with
a diagnosis of intermediate hyperglycaemia (IFG, IGT,
HbA1c) and could transition to T2DM, normoglycaemia
or death, with the probability of transitioning between
states modified by the type of intervention the partici-
pant receives. Participants who were normoglycaemic
could transition to intermediate hyperglycaemia or
death, but not directly to T2DM. To reflect disease
progression/clinical reality participants who transitioned
to T2DM remained in this state until the end of the
modelling period or death (Fig. 1).
For our population-level case study of England, we as-
sumed all adults aged 50–59 years with diagnosed IFG,
IGT or HbA1c would be offered an intervention, but that
only 50% of the population with intermediate hypergly-
caemia would be diagnosed and that 50% who were
offered an intervention would fail to enrol. These
assumptions match those utilised by NICE in the costing
template for diabetes prevention guidance [23], as primary
studies of enrolment and compliance in this area show a
very wide range of participation rates [24]. We assumed
that intermediate hyperglycaemia was diagnosed in one of
two ways, namely (1) an incidental finding when blood
tests were taken for another purpose or (2) through as-
sessment of glycaemic status during an NHS Health
Check England, a clinical assessment offered to all 40–74
year olds in England without pre-existing diabetes or car-
diovascular disease (with coverage of 13.7–22.4% reported
nationally in in the 50–59 year age group) [25].
Model parameters
IFG, IGT and HbA1c are distinct physiological states
and differ in terms of epidemiological parameters, cost
of care and health utilities (Table 1). However, a single
individual may have one, two or three types of inter-
mediate glycaemia concurrently.
Fig. 1 State transition diagram
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Clinical and epidemiological parameters
Diagnostic criteria for prediabetes reflected those of the
NHS Diabetes Prevention Programme [13], WHO
diagnostic criteria for HbA1c and IGT [26], and American
Diabetes Association criteria for IFG [27] (Table 1).
Prevalence of IFG, IGTand at-risk HbA1c, as well as of the
combinations of different types of intermediate hypergly-
caemia, was extracted from a UK-based study [28] and the
annual probability of transitioning to T2DM was obtained
from a meta-analysis with different transition probabilities
assumed for IFG, IGT and HbA1c [10]. All-cause age-stan-
dardised mortality rates were determined from the Office
of National Statistics in England [29], with increased risk of
death calculated for participants with intermediate hyper-
glycaemia or T2DM [30].
For IFG and IGT, relative risks of developing T2DM or
reverting to normoglycaemia with lifestyle interventions
were derived from meta-analyses [8, 15, 20]. Relative risks
for metformin were drawn from the United States
Diabetes Prevention Program Outcomes Study (USDP-
POS) as this is the only long-term follow-up study of this
intervention [31]. To our knowledge, there is only a single
randomised controlled study (a sub-group analysis of the
USDPP) [12] reporting relative risks of participants identi-
fied on the basis of HbA1c. Our model drew from this
single analysis (in which participants also had IGT +/-
IFG). We assumed that the reduction in risk related to met-
formin was constant over 15 years for participants with
IGT and IFG and over 10 years for participants identified
on the basis of HbA1c, as these were the longest periods of
follow-up that have been published for each population [12,
31]. Based on a recent meta-analysis, we assumed that re-
duction in risk declined following cessation of the intensive
lifestyle programme [7] and ceased 10 years after the inter-
vention commenced. As no long term follow-up studies of
pragmatic lifestyle programmes have been undertaken, we
conservatively assumed the risk reduction persisted only for
the duration of the intervention. Finally, we assumed that
adherence was equivalent to that seen in the clinical trials
from which relative risks were derived.
Interventions
The low-intensity lifestyle programme was based on NICE
guidance [32] and includes a core component of 13 group
education sessions in the first year followed by 7 mainten-
ance sessions over the following 2 years, delivered by dia-
betes prevention facilitators, with annual review by a
general practitioner and blood tests by a practice nurse.
The high-intensity lifestyle programme was based on the
USDPP [33], and includes 16 one-to-one education sessions
Table 1 Baseline population – key parameter values
Health state Diagnostic test Diagnostic
criteria
Prevalence Annual
incidence of
T2DM
Annual cost of care (£,
2015)
Utility (QALYs)
Normoglycaemia
(NGT)
Any of fasting blood glucose,
post-load glucose or glycated
haemoglobin
Fasting glucose:
<5.6 mmol/L
Post-load
glucose:
<7.0 mmol/L
HbA1c:
<6.0 mmol/mol
£773
[Gamma distribution,
SE: £102.63]
0.768
[Beta distribution,
SE: 0.10]
Impaired fasting
glucose (IFG)
Fasting blood glucose: blood
glucose test after a period of
fasting (typically overnight)
Fasting glucose:
5.6-6.9 mmol/L
Isolated IFG:
12.76%
IFG + IGT:
1.49%
IFG + HbA1c:
6.61%
IFG + IGT +
HbA1c: 1.06%
3.55%
[Beta distribution,
SE: 0.006]
£869
[Gamma distribution,
SE: 104.56]
0.759
[Beta distribution,
SE: 0.11]
Impaired glucose
tolerance (IGT)
Post-load glucose: blood glucose
test 2 hours after consuming a
drink containing 75 g of sugar
2 hour post-load
glucose: 7.0-11.1
mmol/L
Isolated IGT:
7.50%
IGT + HbA1c:
3.31%
4.54%
[Beta distribution,
SE: 0.004]
£946
[Gamma distribution,
SE: 101.52]
0.746
[Beta distribution,
SE: 0.10]
HbA1c Glycated haemoglobin: blood test
which estimates blood glucose
levels over previous 2-3 months
6.0-6.4 mmol/
mol
Isolated
HbA1c: 7.53%
3.56%
[Beta distribution,
SE:0.017]
£869
[Gamma distribution,
SE: 104.56]
0.759
[Beta distribution,
SE: 0.11]
Type 2 Diabetes
Mellitus (T2DM)
Any of fasting blood glucose,
post-load glucose or glycated
haemoglobin
Fasting glucose:
>6.9 mmol/l
2 hour post-load
glucose: >11.1
mmol/L
£1,179-£2,939
Increasing linearly from
Year 1-15
[Gamma distribution,
SE: 270.00]
0.738
[Beta distribution,
SE: 0.12]
Parametric form and standard error of distribution used in probabilistic sensitivity analysis in italics
Sources: Diagnostic criteria for HbA1c and IGT [26] and for IFG [27], prevalence [28], annual incidence type 2 Diabetes [10], costs [36–39], utilities [40]
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delivered by a dietician and 4 exercise sessions supervised
by a physiotherapist in the first year as well as 12 individual
visits and 4 supervised exercise sessions in the second and
third year. Further, it includes 1–2 reminder phone calls a
month and annual clinical review and blood tests. In terms
of metformin, a dosage of 850 mg twice a day was assumed,
in line with the USDPP [33], with annual titration review
and blood tests by a practice nurse and annual review by a
general practitioner. The low-intensity lifestyle intervention
lasted 2 years, the high-intensity lifestyle intervention lasted
3 years and we assumed that metformin therapy continued
as long as the participant had intermediate hyperglycaemia.
The base case of no intervention assumed that people with
a diagnosis of intermediate hyperglycaemia received no
additional treatment, as was the case in the majority of
England before the commencement of the national pilots in
diabetes prevention in 2017.
Costs (Additional file 1: Appendix 2)
We calculated the costs of lifestyle programmes by ap-
plying Personal Social Services Research Unit (PSSRU)
staff cost estimates [34] to constituent activities de-
scribed in publications regarding the USDPP [33] and
NICE guidance [32], and using published estimates of
diagnostic test costs [35]. We used the British National
Formulary to calculate medication costs [36]. As an
NHS perspective was adopted, we did not include indir-
ect costs such as productivity loss or participants’ out-
of-pocket costs.
Costs of T2DM were determined from a UK study of
resource utilisation in diabetic care [37]. We assumed
costs of diabetes increase linearly over 15 years from the
time of diagnosis to reflect the increasing cost of diabetic
complications over time, in line with the approach taken
by NICE [23]. Costs of other health states were calcu-
lated as proportions of T2DM costs, derived from two
European studies [38, 39]. All costs were inflated to
2015 values. Unrelated healthcare costs (not related to
diabetes or its complications) that accrue due to pro-
longed life were not included in the base case, but were
considered in sensitivity analysis.
Utilities
Utilities were measured in QALYs and were derived for
each health state from a Swedish study that utilised
SF-36 questionnaires, converting responses via the
SF-6D index to utilities [40]. This is the only source of
utilities, to our knowledge, that measured quality of life
in IFG and IGT separately. Incremental utilities associ-
ated with each intervention were drawn from the
USDPP [33], with both low- and high-intensity lifestyle
programmes assumed to be associated with the same in-
cremental utility.
Table 2 outlines the key parameter values, with
Additional file 1: Appendix 1 outlining data sources,
assumptions and limitations of these values.
Analyses
Two types of analyses were undertaken. Firstly, that of
impact on an individual participant in a prevention
programme, followed by impact of a nation-wide
prevention programme, using England as a case study.
Analyses of individual participants included (1) dis-
counted cumulative healthcare costs (including costs of
diagnostic tests and primary and secondary care associ-
ated with the intervention, intermediate hyperglycaemia,
T2DM and complications of T2DM), (2) discounted
QALYs, (3) incidence of T2DM, (4) average number of
years with T2DM, (5) cost-effectiveness ratios in
£/QALY, and (6) incremental cost-effectiveness ratios
(ICERs), in £/QALY (for non-dominated interventions).
Individuals are frequently diagnosed with more than one
type of intermediate hyperglycaemia (Table 1). All par-
ticipants with each type of intermediate hyperglycaemia
(alone or in combination with other types of intermedi-
ate hyperglycaemia) were analysed in each arm of the
model. For example, the IGT arm includes participants
with either IGT in isolation, IGT and IFG, IGT and
HbA1c, or IGT, IFG and HbA1c in the at-risk range.
Analyses of a nation-wide prevention programme
included (1) discounted annual incremental costs, (2)
discounted cumulative incremental costs, (3) discounted
incremental costs as a percentage of the total diabetes
Table 2 Interventions – key parameter values
Intervention Annual cost of intervention
(£, 2015)
Incremental utility associated
with intervention (QALY)
Relative risk of developing T2DM
Pragmatic lifestyle
programme
Yr 1: £203.44
Yr 2: £80.02
0.0189
[Beta distribution, SE: 0.001]
During intervention: IFG: 0.74/IGT: 0.74/HbA1c: 0.74
[Lognormal distribution, SE: 0.11]
Intensive lifestyle
programme
Yr 1: £1225
Yr 2: £689
Yr 3: £671
0.0189
[Beta distribution, SE: 0.001]
During intervention: IFG: 0.63/IGT: 0.55/HbA1c: 0.71
[Lognormal distribution, SE: 0.10 (IFG), 0.07 (IGT), 0.10 (HbA1c)]
Up to 7 years post- intervention: IFG: 0.80/IGT: 0.80/HbA1c: 0.71
[Lognormal distribution, SE: 0.06 (IFG), 0.06 (IGT), 0.10 (HbA1c)]
Metformin £124.25 0.0031
[Beta distribution, SE: 0.002]
IFG: 0.82/IGT: 0.82/HbA1c: 0.62
[Lognormal distribution, SE: 0.05(IGT), 0.05 (IFG), 0.10 (HbA1c)]
Parametric form and standard error of distribution used in probabilistic sensitivity analysis in italics
Sources: Intervention costs (calculated – see Additional file 1: Appendix 2), incremental utilities [32], relative risks [8, 12, 15, 20, 21]
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expenditure [17], and (4) cumulative incidence of
T2DM. To account for individuals with multiple types of
intermediate hyperglycaemia, the costs and effects in the
IGT arm of the analysis was assumed to represent all in-
dividuals with a diagnosis of IGT (participants with IGT
in isolation, IGT and IFG, IGT and HbA1c in the at-risk
range, and IGT, IFG and HbA1c in the at-risk range),
the costs and effects in the IFG arm of the analysis was
assumed to represent all individuals with isolated IFG
and with IFG and HbA1c in the at-risk range, and the
costs and effects of the HbA1c arm of the analysis was
assumed to represent all individuals with isolated HbA1c
in the at-risk range.
Sensitivity analyses
We assessed parameter uncertainty with (1) determinis-
tic one-way sensitivity analysis, altering all parameter
values by ±10%, (2) probabilistic sensitivity analysis and
(3) deterministic scenario analyses where primary clin-
ical data was not available to create a distribution (e.g.
duration of intervention effect) or differences in clinical
definitions existed (e.g. IFG diagnosed by WHO criteria).
Validation
We validated the model in accordance with the AdVISHE
(Assessment of the Validation Status of Health-Economic
Decision Models) checklist [41] (Additional file 1: Appendix
6). Three experts tested the face validity of the model struc-
ture, inputs and outputs, and their suggestions were incor-
porated in the final model. Extreme value testing and audit
of Markov cohort traces was undertaken by the authors
and the structure of formulae were reviewed in a session
with the TreeAge support team. Model outputs were
validated against empirical data, including mortality data
for England and estimates of current prevalence of T2DM
by age group.
Results
Outcomes for individual participants in a prevention
programme
The base case results of deterministic sensitivity analysis
are presented in Tables 3, 4, and 5. In participants with all
types of intermediate hyperglycaemia, pragmatic lifestyle
programmes, intensive lifestyle programmes and metfor-
min all increased costs, improved QALYs and reduced
diabetes incidence compared with no intervention.
Incremental cost-effectiveness ratios (ICERs) – comparison
with the next best alternative
For all three populations, the low-intensity lifestyle
programme was the most cost-effective option, with ICERs
of £44/QALY, £195/QALY and £186/QALY in populations
with IGT, IFG and HbA1c in the at-risk range, respectively.
At the current NICE willingness-to-pay threshold of
£20,000/QALY, intensive lifestyle interventions were cost-
effective relative to the next best alternative (low-intensity
lifestyle programme), with ICERs of £3707 and £11,219 for
IGT and IFG, respectively. For the population with HbA1c
in the at-risk range, metformin was also found to be cost-
effective relative to the next best alternative (low-intensity
lifestyle programmes), with an ICER of £600/QALY; this
was the only population for which metformin was not
extendedly dominated (a combination of pragmatic and in-
tensive lifestyle interventions was not more cost-effective
than metformin) (Table 5, Fig. 2). However, due to effect
sizes in participants with HbA1c being derived from a sin-
gle clinical study, results for this population should be
treated cautiously. At a willingness-to-pay threshold of
£20,000/QALY, the probability of being cost-effective rela-
tive to the next best alternative was 98%, 99% and 98% for
low-intensity lifestyle programmes and 75%, 75% and 40%
Table 3 Costs and consequences for individual participants in a
prevention programme
Method of
identifying
participants
Intervention Total cost
(£,2015)
Total
QALYs
Prevalence
of T2DM
after 50
years (%)
Average
number
of years
lived with
T2DM after
50 years
IGT No
intervention
17,772 11.53 42% 5.75
Pragmatic
lifestyle
programme
17,774 11.59 41% 5.43
Intensive
lifestyle
programme
18,423 11.76 33% 3.97
Metformin 17,988 11.60 38% 5.03
IFG No
intervention
17,429 12.13 38% 5.34
Pragmatic
lifestyle
programme
17,440 12.19 37% 5.07
Intensive
lifestyle
programme
18,452 12.28 31% 3.98
Metformin 17,908 12.20 35% 4.68
HbA1c No
intervention
17,436 12.13 38% 5.35
Pragmatic
lifestyle
programme
17,446 12.19 37% 5.08
Intensive
lifestyle
programme
18,507 12.27 31% 4.03
Metformin 17,475 12.23 33% 4.18
Differences between costs and QALYs of ‘no intervention’ in the groups with
IGT, IFG and HbA1c are due to: 1) higher hazard ratios of death with IGT
relative to IFG/HbA1c, ii) lower baseline utilities for IGT relative to IFG/HbA1c
and iii) higher baseline transition probabilities to T2DM with IGT relative to
IFG/HbA1c, as outlined in Additional file 1: Appendix 1
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for high-intensity lifestyle programmes for participants
with IGT, IFG and HbA1c, respectively. The probability
that metformin was cost-effective relative to the next best
alternative was 50% for participants with HbA1c
(Additional file 1: Appendix 5).
Cost-effectiveness ratios – comparison with no intervention
Compared to no intervention, the low-intensity lifestyle
programme was the most cost-effective option with
cost-effectiveness ratios of £44/QALY, £195/QALY and
£186/QALY in populations with IGT, IFG and HbA1c in
the at-risk range, respectively. Cost-effectiveness of inten-
sive lifestyle interventions were £2775/QALY, £6820/
QALY and £7376/QALY and of metformin were £5224/
QALY, £6842/QALY and £372/QALY relative to no
intervention for IGT, IFG and HbA1c, respectively
(Table 5, Fig. 2). At a willingness-to-pay threshold of
£20,000/QALY, the probability of being cost-effective
was 98%, 99% and 98% for low-intensity lifestyle pro-
grammes, 81%, 81% and 71% for high-intensity lifestyle
programmes, and 76%, 76% and 78% for metformin in
participants with IGT, IFG and HbA1c, respectively
(Additional file 1: Appendix 5).
Effect on diabetes prevalence
With no intervention, 42% of the IGT population and
38% of the IFG and HbA1c population developed T2DM
over 50 years. Diabetes incidence was reduced to 41%,
33% and 38% in the IGT population, 37%, 31% and 35%
in the IFG population, and 37%, 31% and 33% in the
HbA1c population with pragmatic lifestyle programmes,
intensive lifestyle programmes and metformin, respect-
ively (Table 4).
Table 4 Diabetes incidence and risk reduction over 10 years and 50 years
Method of
identifying
participants
No intervention Low intensity lifestyle programme High intensity lifestyle programme Metformin
Incidence T2DM Incidence T2DM Relative risk
reduction
Incidence
T2DM
Relative risk
reduction
Incidence T2DM Relative risk
reduction
After
10 years
After
50 years
After
10 years
After
50 years
At
10 years
At
50 years
After
10 years
After
50 years
At
10 years
At
50 years
After
10 years
After
50 years
At
10 years
At
50 years
IGT 23% 42% 22% 41% 7% 3% 14% 33% 39% 21% 20% 38% 16% 9%
IFG 19% 38% 18% 37% 7% 3% 13% 31% 35% 17% 16% 35% 16% 9%
HbA1c 19% 38% 18% 37% 7% 3% 13% 31% 35% 17% 13% 33% 35% 14%
Table 5 Incremental cost effectiveness ratios and cost-effectiveness relative to no intervention for individual participants in a
prevention programme
Method of
identifying
participants
Intervention Incremental cost effectiveness ratio (ICER)
(relative to next best intervention)
Cost effectiveness ratio (CER)
(relative to no intervention)
Incremental
cost (£, 2015)
Incremental
effect (QALYs)
ICER
(£/QALY)
Probability ICER
< £20,000/QALY
Cost vs no
intervention
(£, 2015)
Effect vs no
intervention
(QALYs)
CER
(£/QALY)
Probability CER
< £20,000/QALY
IGT No intervention - - - - - - - -
Low-intensity
lifestyle
3 0.06 44 98.19% 3 0.06 44.33 98.19%
Metformin Subject to extended dominance 367 0.07 5,224 75.86%
High-intensity
lifestyle
649 0.18 3,707 74.58% 652 0.23 2,775 80.5%
IFG No intervention - - - - - - - -
Low-intensity
lifestyle
11 0.06 195 98.5% 11 0.06 195 98.5%
Metformin Subject to extended dominance 479 0.07 6,842 76.28%
High-intensity
lifestyle
1,012 0.09 11,219 75.09% 1,023 0.15 6,820 81.44%
HbA1c No intervention - - - - - - - -
Low-intensity
lifestyle
11 0.06 186 97.79% 11 0.06 186 97.79%
Metformin 28 0.05 600 50.40% 39 0.10 372 77.89%
High-intensity
lifestyle
1,032 0.04 25,481 40.38% 1,071 0.15 7,376 71.28%
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Outcomes of a nation-wide prevention programme
Incident cases of T2DM would be reduced by 0.3–1.5%
over 50 years in those aged 50–59 years if a pragmatic
lifestyle programme was offered to everyone with a diag-
nosis of either IFG, IGT or HbA1c in the at-risk range in
this age group in England (Table 6). A national intensive
lifestyle programme would lead to the greatest population
health benefits, with a 1.9–3.1% reduction in diabetes inci-
dence and 2.7–3.4% reduction in the number of years with
T2DM. The type of prediabetes has a significant impact on
population-level outcomes due to the substantially higher
prevalence of IFG and high HbA1c than IGT.
Annual incremental costs are negative from year 3 for
pragmatic lifestyle programmes, from year 4 for intensive
lifestyle programmes and from year 10 for metformin,
relative to no intervention (Fig. 3). Cumulative costs re-
main positive over the 50-year modelling period relative
to no intervention (Fig. 4). Assuming no existing diabetes
services are displaced, an England-wide prevention
programme requires an investment (as a percentage of
total diabetes costs) of 0.5–0.9% in year 1 and 0.2–0.3% in
year 2 for a pragmatic lifestyle intervention, and 3.1–5.2%
in year 1, 1.4–2.3% in year 2 and 1.0–1.8% in year 3 for an
intensive lifestyle programme, depending on the type of
participants targeted (Additional file 1: Appendix 3).
Sensitivity analysis
Key factors impacting cost-effectiveness calculations in
one-way sensitivity analysis were health state utilities,
hazard ratios of death, relative risks of T2DM and costs
of the interventions. Additional scenarios examining ex-
tended duration of intervention effect, use of WHO cri-
teria to diagnose IFG, increased/decreased intervention
costs and inclusion of unrelated healthcare costs
(Additional file 1: Appendix 4) resulted in differences
from the base case analysis. Firstly, pragmatic lifestyle
Fig. 2 Cost-effectiveness plane: incremental cost and QALYs relative to no intervention
Table 6 Outcomes for an England-wide prevention programme
Method of identifying
participants
Intervention Reduction in incident
cases of T2DM
(number of cases)
% reduction in
incident cases
of T2DM
Reduction in
average number
of years lived
with T2DM
(number of years)
% reduction in
average number
of years lived
with T2DM (%)
IGT Pragmatic lifestyle programme 2,938 0.3% 0.03 0.5%
Intensive lifestyle programme 20,494 1.9% 0.15 2.7%
Metformin 9,388 1.9% 0.07 1.3%
IFG Pragmatic lifestyle programme 11,582 1.1% 0.04 0.7%
Intensive lifestyle programme 32,119 3.0% 0.19 3.4%
Metformin 20,863 1.9% 0.11 2.0%
HbA1c Pragmatic lifestyle programme 15,856 1.5% o.03 0.6%
Intensive lifestyle programme 33,027 3.1% 0.15 2.8%
Metformin 29,163 2.7% 0.14 2.5%
Roberts et al. BMC Medicine  (2018) 16:16 Page 8 of 12
programmes are cost-saving in all participants when
intervention effect is extended. Secondly, pragmatic life-
style programmes are cost saving if the WHO criteria
are used to diagnose IFG, with reduced budget impact at
a population level but fewer cases of T2DM prevented.
Thirdly, metformin is cost saving in participants with
HbA1c when intervention effect is extended. Finally,
intensive lifestyle programmes are cost-effective in
participants with HbA1c when intervention costs were
decreased by 20%. All interventions remained cost-
effective relative to no intervention when unrelated
healthcare costs were included in the analysis.
Discussion
Principal findings
This study has produced six major findings. Firstly, low-
intensity lifestyle interventions are the lowest cost diabetes
prevention programme over a participant’s lifetime in all
types of intermediate hyperglycaemia. Secondly, high-
intensity lifestyle interventions deliver the greatest health
benefit in terms of reducing diabetes incidence, years lived
with T2DM and QALYs gained in participants with all types
of intermediate hyperglycaemia. Thirdly, at a population-
level, the type of intervention has the greatest impact on
costs while the type of intermediate hyperglycaemia used
for inclusion in prevention programmes has the greatest
impact on percentage reduction in incident cases. Fourthly,
low- and high-intensity lifestyle programmes are very cost-
effective in participants with IFG and IGT, while metformin
is not a cost-effective option in these populations; these
results were consistent across a range of parameter values.
Fifthly, while budget impact as a percentage of total
diabetes expenditure is small, these interventions require a
net increase in diabetes expenditure (assuming existing ser-
vices are not displaced) over 2, 3 and 9 years in the case of
Fig. 3 Annual incremental costs of an England-wide programme
Fig. 4 Cumulative cost of an England-wide programe
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low-intensity lifestyle, high-intensity lifestyle and metfor-
min, respectively. Subsequent savings due to reduced inci-
dence of T2DM are insufficient to entirely offset this
increased expenditure. Finally, impact on incidence of
T2DM at a population level is small due to the lack of over-
lap between different types of intermediate hyperglycaemia
and issues with participation in screening tests, adherence
to interventions and attenuation in the treatment effect
over time.
This study’s results are comparable with previously
published economic evaluations of diabetes prevention
programmes, which found ICERs ranging from cost sav-
ing to £134,420/QALY with a median value of £7490/
QALY for lifestyle programmes, and ranging from cost
saving to £32,430/QALY with a median value of £8428/
QALY for metformin [15] in comparison to no interven-
tion. Differences in assumptions regarding intervention
cost and effect and uncertainty regarding key parameter
values (e.g. duration of intervention effect), account for
the range of ICERs in published economic evaluations.
Implications for policymakers
This study provides a quantification of a number of key
tensions in diabetes prevention policy, including (1)
whether to select participants for which interventions
will be the most cost-effective (those with IGT) or par-
ticipants identified by tests that are widely used in
current clinical practice (those with high HbA1c or
IFG), (2) whether to target interventions at populations
with the most attractive ICERs (those with IGT) or
populations in which the greatest population-wide im-
pact could be achieved (those with IFG according to
American Diabetes Association criteria), and (3) whether
to minimise budget impact by providing low-intensity
lifestyle programmes or maximise reduction in diabetes
incidence and QALYs gained by providing high-intensity
lifestyle programmes.
On balance, this analysis suggests that current English
national policy of targeting prevention programmes at
participants with IFG or HbA1c, and not recommending
metformin as first-line prevention, will be cost-effective
and have the most favourable budget impact. However,
the modest reduction in incidence of T2DM importantly
suggests that this approach will be insufficient to address
the substantial growth in diabetes forecast for the com-
ing decades. Therefore, the search for additional inter-
ventions should continue.
We did not formally evaluate costs and effects in other
countries. However, effect sizes in this model are drawn
from international studies, and therefore our conclusions
regarding gains in QALYs, reduction in incidence of
T2DM and years with T2DM should be broadly general-
isable, assuming equivalent prevalence of intermediate
hyperglycaemia.
Strengths and limitations
This study adds to previous economic evaluations by
quantifying the impact of different types of intermedi-
ate hyperglycaemia and different intensities of lifestyle
programme as well as by estimating costs and conse-
quences at an individual participant level and a na-
tional programme level, using a case study of
England. This study’s limitations include the availabil-
ity of primary clinical data and the structure and
scope of the Markov model. In terms of data avail-
ability, there were limited primary clinical data from
trials to model participants with intermediate hyper-
glycaemia identified by HbA1c, quantify the long-term
effect of pragmatic lifestyle interventions, differentiate
the reduction in diabetes incidence due to low-
intensity lifestyle interventions by type of intermediate
hyperglycaemia, or evaluate the long-term effects of
metformin in isolation by age group, since the USDPP
Outcomes Study data used in this analysis relates to a
cohort that received lifestyle advice in addition to
metformin from year 4 of the 10-year intervention.
Another major shortcoming is the absence of
evidence on the impact of lifestyle on endpoints im-
portant to patients such as, for example, the compli-
cation of diabetes and death. In terms of the model
structure, we elected to use a Markov model to
compare our findings with those of previous eco-
nomic evaluations, the majority of which use Markov
models [15]. However, the underlying physiological
changes in intermediate hyperglycaemia and diabetes
are continuous variables (fasting glucose, post-load glu-
cose or HbA1c), which are better suited to simulation
modelling. In addition, simulation modelling requires
more detailed data which were not available for all types
of participants and interventions modelled. In terms of
the scope of the model, we modelled only costs and
QALYs relating to diabetes and its complications, whereas
interventions may have beneficial effects on other types of
disease (e.g. obesity-related cancers, dementia) that are
not captured, but would likely improve the cost-
effectiveness of lifestyle programmes. In addition, we did
not explicitly model adverse effects of metformin, which
we assumed were accounted for in the lower incremental
utilities associated with metformin relative to lifestyle
programmes.
Suggestions for future research
This study has confirmed five areas where further
research would be beneficial. Firstly, evaluating the
effect of lifestyle programmes and metformin in
participants identified on the basis of HbA1c. Sec-
ondly, undertaking longer term follow-up of prag-
matic lifestyle programmes to evaluate the duration
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and profile of the reduction in risks of T2DM.
Thirdly, evaluating the impact of lifestyle programmes
on the complications of T2DM, including death.
Fourthly, modelling the effects of diabetes prevention
programmes on other obesity-related diseases. Finally,
consideration of the role of broader social and envir-
onmental programmes (e.g. sugar tax, changes to the
physical environment) on diabetes incidence as, based
on the findings of this study, individual lifestyle pro-
grammes and metformin are unlikely to be sufficient
to address the vast majority of incident cases of
T2DM.
Conclusions
Different categories of intermediate hyperglycaemia
and varying intensities of lifestyle intervention do lead
to differences in the cost-effectiveness of diabetes
prevention programmes. Low- and high-intensity life-
style programmes are cost-effective in participants
with IFG or IGT. Metformin appears cost-effective in
populations with HbA1c in the at-risk range; however,
these results should be treated cautiously due to the
lack of primary clinical data on the effects of preven-
tion programmes in participants with isolated high
HbA1c. No single option has the most attractive
cost-effectiveness profile, budget impact and impact
on incident cases of T2DM or years with T2DM, with
prevention policy facing a trade-off between these
factors.
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